Search Results - "Yen, Karl"

Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation by Flume, Patrick A., MD, FCCP, Liou, Theodore G., MD, FCCP, Borowitz, Drucy S., MD, Li, Haihong, PhD, Yen, Karl, MD, Ordoñez, Claudia L., MD, Geller, David E., MD

“…Background Ivacaftor (VX-770) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that was approved in the United States for the…”
Get full text

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy by Muntoni, Francesco, Byrne, Barry J., McMillan, Hugh J., Ryan, Monique M., Wong, Brenda L., Dukart, Juergen, Bansal, Amita, Cosson, Valerie, Dreghici, Roxana, Guridi, Maitea, Rabbia, Michael, Staunton, Hannah, Tirucherai, Giridhar S., Yen, Karl, Yuan, Xiling, Wagner, Kathryn R.

“…Introduction Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and is ultimately fatal. Recently approved…”
Get full text

Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials by Hanania, Nicola A., MD, Noonan, Michael J., MD, Corren, Jonathan, MD, Korenblat, Phillip, MD, FAAAAI, Zheng, Yanan, PhD, Putnam, Wendy, PhD, Murray, Elaine, MD, Abelardo, Connie, MD, Scheerens, Heleen, PhD, Maciuca, Romeo, PhD, Gray, Sarah, PhD, Doyle, Ramona, MD, McClintock, Dana, MD, Matthews, John G., MBBS, MRSCP, PhD, Yen, Karl, MD, MMSc, FAAP

Get full text

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) by Simpson, Eric L., Flohr, Carsten, Eichenfield, Lawrence F., Bieber, Thomas, Sofen, Howard, Taïeb, Alain, Owen, Ryan, Putnam, Wendy, Castro, Marcela, DeBusk, Kendra, Lin, Chin-Yu, Voulgari, Athina, Yen, Karl, Omachi, Theodore A.

“…Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). We investigated the efficacy and…”
Get full text

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies by Hanania, Nicola A, Noonan, Michael, Corren, Jonathan, Korenblat, Phillip, Zheng, Yanan, Fischer, Saloumeh K, Cheu, Melissa, Putnam, Wendy S, Murray, Elaine, Scheerens, Heleen, Holweg, Cecile T J, Maciuca, Romeo, Gray, Sarah, Doyle, Ramona, McClintock, Dana, Olsson, Julie, Matthews, John G, Yen, Karl

“…In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches…”
Get more information

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation by DAVIES, Jane C, WAINWRIGHT, Claire E, ORDONEZ, Claudia L, AHRENS, Richard, CANNY, Gerard J, CHILVERS, Mark A, HOWENSTINE, Michelle S, MUNCK, Anne, MAINZ, Jochen G, RODRIGUEZ, Sally, HAIHONG LI, YEN, Karl

“…Ivacaftor (VX-770), a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been shown to improve lung function, pulmonary exacerbation…”
Get full text

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation by Ramsey, Bonnie W, Davies, Jane, McElvaney, N. Gerard, Tullis, Elizabeth, Bell, Scott C, Dřevínek, Pavel, Griese, Matthias, McKone, Edward F, Wainwright, Claire E, Konstan, Michael W, Moss, Richard, Ratjen, Felix, Sermet-Gaudelus, Isabelle, Rowe, Steven M, Dong, Qunming, Rodriguez, Sally, Yen, Karl, Ordoñez, Claudia, Elborn, J. Stuart

“…Ivacaftor, a potentiator of CFTR, was studied in patients with cystic fibrosis (CF) who had mutations that reduced the function of the CFTR protein. Ivacaftor…”
Get full text

Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study by Murrell, Dedee F, Caux, Frédéric, Patsatsi, Aikaterini, Hagino, Owen, Rudnicka, Lidia, Vassileva, Snejina, Uzun, Soner, Ye, Jenny, Yen, Karl, Arora, Puneet, Gourlay, Steven G, Joly, Pascal, Werth, Victoria P

“…Pemphigus is a rare but life-threatening autoimmune disease requiring long-term treatment that minimizes corticosteroid (CS) exposure while providing…”
Get more information

661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD) by Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim, Reich, Adam, Lee, Chih-Hung, Worm, Margitta, Lynde, Charles, Kataoka, Yoko, Foley, Peter, Weber, Christine, Solente, Anne-Catherine, Adelman, Samuel, Davey, Sonya, Wong, Wanling, Rynkiewicz, Natalie, Yen, Karl, O’Malley, John T, Bernigaud, Charlotte

“…Abstract Background Amlitelimab is a fully-human, non-depleting, anti-OX40 ligand (OX40L) monoclonal antibody that binds to OX40L on antigen-presenting cells…”
Get full text

523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD) by Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim, Reich, Adam, Lee, Chih-Hung, Worm, Margitta, Lynde, Charles, Kataoka, Yoko, Foley, Peter, Weber, Christine, Wong, Wanling, Hurbin, Fabrice, Rynkiewicz, Natalie, Yen, Karl, Wei, Xiaodan, O’Malley, John T, Bernigaud, Charlotte

“…Abstract Introduction/Background Targeting and binding OX40 ligand (OX40L) expressed on antigen-presenting cells may inhibit the persistent immune response…”
Get full text

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation by Clancy, J P, Rowe, Steven M, Accurso, Frank J, Aitken, Moira L, Amin, Raouf S, Ashlock, Melissa A, Ballmann, Manfred, Boyle, Michael P, Bronsveld, Inez, Campbell, Preston W, De Boeck, Kris, Donaldson, Scott H, Dorkin, Henry L, Dunitz, Jordan M, Durie, Peter R, Jain, Manu, Leonard, Anissa, McCoy, Karen S, Moss, Richard B, Pilewski, Joseph M, Rosenbluth, Daniel B, Rubenstein, Ronald C, Schechter, Michael S, Botfield, Martyn, Ordoñez, Claudia L, Spencer-Green, George T, Vernillet, Laurent, Wisseh, Steve, Yen, Karl, Konstan, Michael W

“…VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR…”
Get more information

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis by Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim A., Reich, Adam, Lee, Chih-Hung, Worm, Margitta, Lynde, Charles, Kataoka, Yoko, Foley, Peter, Wei, Xiaodan, Wong, Wanling, Solente, Anne-Catherine, Weber, Christine, Adelman, Samuel, Davey, Sonya, Hurbin, Fabrice, Rynkiewicz, Natalie, Yen, Karl, O’Malley, John T., Bernigaud, Charlotte

“…[Display omitted] Amlitelimab, a fully human nondepleting monoclonal antibody targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven…”
Get full text

Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials by Servais, Laurent, Yen, Karl, Guridi, Maitea, Lukawy, Jacek, Vissière, David, Strijbos, Paul

“…In 2019, stride velocity 95th centile (SV95C) became the first wearable-derived digital clinical outcome assessment (COA) qualified by the European Medicines…”
Get more information

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids by Korenblat, Philip, Kerwin, Edwin, Leshchenko, Igor, Yen, Karl, Holweg, Cecile T.J., Anzures-Cabrera, Judith, Martin, Carmen, Putnam, Wendy S., Governale, Laura, Olsson, Julie, Matthews, John G.

“…Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to…”
Get full text

Sports-specific concerns in the young athlete: Baseball by YEN, KARL L, METZL, JORDAN D

“…The sport of baseball is played by millions of children across America and around the world. Although generally considered a safe activity, it is estimated…”
Get full text

A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062) by Wagner, Kathryn R., Wong, Brenda L., Byrne, Barry J., Tian, Cuixia, Jacobsen, Leslie K., Tirucherai, Giridhar S., Rabbia, Michael, Kletzl, Heidemarie, Dukart, Juergen, Ong, Rose, Yen, Karl, Sajeev, Gautam, Signorovitch, James, Ward, Susan J., Bechtold, Cliff, Krishnan, Michelle

“…Abstract only…”
Get full text

Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease by Caswell-Smith, R., Hosking, A., Cripps, T., Holweg, C., Matthews, J., Holliday, M., Maillot, C., Fingleton, J., Weatherall, M., Braithwaite, I., Beasley, R.

“…Summary Background The clinical utility of serum periostin as a type 2 biomarker in asthma is limited by lack of reference range values derived from a…”
Get full text

Nasal Biomarkers Characterization In Lebrikizumab Bronchoscopy Study (CLAVIER) by Cai, Fang, Abreu, Francis, Ding, Han Ting, Choy, David, Bremer, Meire, Staton, Tracy, Erickson, Rich, Peng, Kun, Wang, Jian Shuang, Au-Yeung, Amelia, Hansel, Trevor T., Bjermer, Leif, Holweg, Cecile, Yen, Karl, Matthews, John G., Scheerens, Heleen

“…Methods We implemented an optional nasosorption substudy in a mechanistic, bronchoscopy study (CLAVIER) of lebrikizumab (an anti-IL13 monoclonal antibody) in…”
Get full text

Bidi cigarettes: An emerging threat to adolescent health by Yen, K L, Hechavarria, E, Bostwick, S B

Get more information

Household oven doors: a burn hazard in children by Yen, K L, Bank, D E, O'Neill, A M, Yurt, R W

“…Contact with hot oven doors is an important cause of burns in pediatric patients. These burns are of particular concern because of their frequent localization…”
Get more information